Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Metals Report
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
Kimberly Lee, D.O., is a senior research analyst at ThinkEquity LLC, where she focuses on the biotechnology sector. Prior to joining ThinkEquity she covered the biotechnology industry for more than 11 years, most recently as a managing director at Global Hunter Securities LLC. She has also held sell-side roles at Stephens Inc., Jefferies & Co. Inc. and Wedbush Securities (formerly Pacific Growth Equities). Prior to her Wall Street career, Lee was trained as an obstetrician/gynecologist. She holds a bachelor's degree in biological sciences from Stanford University and earned her doctorate in osteopathic medicine from Kirksville College of Osteopathic Medicine.
ThinkEquity Analyst Bets on Extraordinary Science and Clinical Data (9/20/12) Investing in companies devoted to orphan diseases sounds counterintuitive, but Senior Research Analyst Kimberly Lee of ThinkEquity has singled out the space as one with the potential for huge returns. In this exclusive interview with The Life Sciences Report, Lee shares her very best ideas, identifying companies that will be propelled by vigorously growing revenues and will also appeal to investors who understand the unmet needs of patients and the numerous incentives available for developing life-saving drugs.
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >